We herein report the case of a 75-year-old man who developed an increased serum creatinine level (4.93 mg/dL) and oliguria with massive proteinuria (7.14 g/day) on the second day after a single oral administration of high-dose (56 mg) minodronate. The histology of a renal biopsy showed one area of glomerular sclerosis among 20 glomeruli with global foot process effacement of podocytes and mild infiltration of lymphocytes and eosinophils into the interstitial space. Acute kidney injury in nephrotic syndrome due to focal segmental glomerular sclerosis induced by minodronate was diagnosed. Following cessation of minodronate without the administration of immunosuppressive agents, the patient's renal function and proteinuria markedly improved.
Introduction
Bisphosphonate is widely used for the treatment of osteoporosis, tumor-associated osteolysis and hypercalcemia (1) . It has been suggested that bisphosphonate inhibits the functions of osteoclasts by inhibiting several signaling pathways and inducing cytotoxic metabolites (2) . On the other hand, bisphosphonate may damage podocytes in glomeruli because there is a certain similarity in protein structure between osteoclasts and podocytes (2) . Indeed, several types of nephrotic syndrome induced by bisphosphonate have been reported (3) (4) (5) (6) (7) . Recently, the dosage regimen of oral bisphosphonates was changed from daily to weekly or monthly administration in order to increase patient adherence and drug efficacy in terms of the incidence of vertebral fractures (8) .
Minodronate is the first bisphosphonate to be effective for preventing osteoporosis via high-dose (50 mg) oral admin-istration on a monthly basis. We herein describe a case of acute kidney injury (AKI) in a patient with nephrotic syndrome due to focal segmental glomerular sclerosis (FSGS) induced by a single oral administration of 50 mg of minodronate.
Case Report
A 75-year-old Japanese man was diagnosed with osteoporosis. His primary care physician initiated weekly oral treatment with 35 mg of alendronate and 0.5 μg of alfacalcidol in April 2009 at a local hospital. Although no abnormalities had been identified on blood tests or urinalyses before or after taking these agents, a blood test performed on February, 2012 showed that the serum creatinine (Cr) level was 0.96 mg/dL. Based on this finding, the estimated glomerular filtration rate (eGFR) was calculated to be 58.8 mL/min/1.73 m 2 (9) . Therefore, the patient was retroactively classified as having stage 3 chronic kidney disease (CKD) (10) . The alendronate was changed to 50 mg of minodronate administered orally on March, 2012 to ensure drug adherence. Edema in the eyelids and lower legs developed, and the patient's urine volume rapidly decreased two days after the first oral administration of minodronate. His body weight increased from 55 kg to 69.6 kg. Therefore, he consulted his primary care physician and underwent blood and urinary analyses. The tests showed that the serum Cr level had increased to 1.27 mg/dL (eGFR: 43.3 mL/min/1.73 m 2 ) with the development of proteinuria. The patient was admitted to the hospital and consulted a nephrologist. After admission, the oliguria (300-400 mL/day) continued, and the serum Cr level progressively increased to 5.19 mg/dL (eGFR: 5.19 mL/min/1.73 m 2 ) with massive proteinuria (17.3 g/gCr) and hematuria (5-9/high-power field). The serum albumin (Alb) level decreased to 2.5 g/L. Therefore, the patient was transferred to our nephrology center for diagnosis and treatment of renal disease on April, 2012. On an examination performed at admission, he was found to have systemic edema. His blood pressure was 142/92 (systolic/diastolic) mmHg. A blood analysis showed that the serum Cr level was 4.93 mg/ dL (eGFR: 4.93 mL/min/1.73 m 2 ), the blood urea nitrogen level was 82 mg/dL and the serum Alb level was 1.4 g/dL.
A urinalysis revealed proteinuria of 7.24 g/day with hematuria (20-30/each field). Table 1 shows the blood test and urinalysis results obtained on admission and those obtained before minodronate administration. The patient was diagnosed with AKI in nephrotic syndrome based on these results. A renal biopsy was performed to investigate the pathology of the AKI in nephrotic syndrome. A light microscopic analysis showed one area of glomerular sclerosis ( Fig. 1A ) among 20 glomeruli with normal basement membranes and no increases in the mesangial matrix or cellularity ( Fig. 1B) with mild infiltration of lymphocytes and eosinophils in the interstitial space (Fig. 1C, arrow ). An immunofluorescent analysis showed no deposition of immunoglobulin (IgA, IgG, IgM), complement (C3c, C1q, C4) or fibrinogen in the glomeruli. An electron microscopic analysis showed global foot process effacement of podocytes ( Fig. 1D ). Based on the patient's clinical history and findings, we diagnosed him with AKI in nephrotic syndrome due to FSGS induced by a single oral administration of minodronate. Therefore, he was treated with furosemide to maintain his urine volume at an appropriate level and warfarin to prevent overcoagulation without the administration of any immunosuppressive agents. Subsequently, the serum Cr level markedly decreased to <1.5 mg/dL on the 14th hos- pital day. The proteinuria also decreased to 0.30 g/day on the 20th hospital day (Fig. 2 ).
Discussion
We herein described a case of AKI in nephrotic syndrome due to FSGS induced by a single oral administration of high-dose (50 mg) minodronate. It has been reported that bisphosphonates can induce renal injury. Yilmaz et al. reported a case of FSGS induced by weekly oral administration of 70 mg of alendronate for four months. In that case, the kidney biopsy specimens demonstrated two areas of global sclerosis among 34 glomeruli. An immunofluorescent study showed no specific deposition of immunoglobulin or complement (7) . Markowitz et al. also reported seven FSGS cases induced by intravenous pamidronate administration for 15 to 48 months. In those cases, since the renal biopsy specimens exhibited FSGS with no immunoglobulin or complement deposition with sparse interstitial infiltration of immune cells, the authors suggested that pamidronate-induced renal damage is mediated by direct toxic effects rather than immunologic reactions induced by pamidronate (3) . In the present case, we also observed FSGS with no immunoglobulin or complement deposition with interstitial infiltration of immune cells following minodronate administration. These findings are consistent with those of previous cases. Previous case reports of renal impairment caused by oral bisphosphonate administration are summarized in Table 2 (4-7). Although the mechanisms underlying the nephrotoxicity of bisphosphonates are not fully understood, bisphosphonates have been reported to inhibit the mevalonate pathway within osteoclasts, leading to alterations in integrin signals, endosomal trafficking, membrane ruffling and induction of apoptosis (11) . Bisphosphonates have also been reported to impair cellular energetic processes and disrupt cytoskeleton assembly within osteoclasts (12, 13) . On another front, the effects of bisphosphonates on osteoclasts may contribute to damage within podocytes, leading to renal injury because podocytes have a cytoskeleton complex that is similar to that of osteoclasts (2) . In the present case, we found global foot process effacement of podocytes in an electron microscopic analysis. Although further studies are needed to investigate the mechanisms of renal injury caused by minodronate, these results suggest that podocyte injury induced by minodronate contributed to the development of AKI with nephrotic syndrome in the present case.
Recently, the dosage regimen of oral bisphosphonates was changed from daily to weekly or monthly administration in order to increase patient adherence and drug efficacy. Minodronate is the first bisphosphonate that can be administered orally once per month for the treatment of osteoporosis (14) . Monthly oral administration of 50 mg of minodronate has much more efficacy in terms of the incidence of vertebral fractures (2.2% in a group receiving oral administration of 1 mg of minodronate daily vs. 0.9% in a group receiving oral administration of 50 mg once per month) (8) . The dosedependent nephrotoxicity of bisphosphonate has been reported in animal models (15) . Since the oral administration of high-dose (56 mg) minodronate produces more than 20fold higher maximum plasma concentrations than the oral administration of 1 mg of minodronate (based on the package insert of Bonoteo), it is possible that such a high plasma minodronate concentration can induce renal damage. The present patient was retrospectively classified as having stage 3 CKD before minodronate administration. His decreased renal function may have contributed to the increased plasma minodronate concentration and enhanced the drug's toxicity for the development of AKI in nephritic syndrome. The prevalence of stage 3 CKD increases in association with age. The prevalence of stage 3 CKD is 44.0% and 59.1% in the age groups of 70-79 years of age and 80-89 years of age, respectively, in Japan (16) . Since a large proportion of elderly people have CKD, high-dose minodronate administration in elderly patients should be carefully considered in each case.
In conclusion, the clinical observations, laboratory data and results of a renal biopsy specimen suggested a diagnosis of AKI in nephrotic syndrome due to FSGS induced by a single oral administration of high-dose minodronate in this case. Urinalyses should therefore be performed and the renal function should be regularly monitored in association with an appropriate degree of clinical care and observation after the initiation of the oral administration of high-dose bisphosphonate.
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